Literature DB >> 29247447

Relationships of oxidized HDL with blood coagulation and fibrinolysis in patients with type 2 diabetes mellitus.

Shigeyuki Ebara1,2, Mikio Marumo1, Jun Mukai3, Makoto Ohki3, Kagehiro Uchida3, Ichiro Wakabayashi4.   

Abstract

Although oxidization of LDL is known to be a crucial step for atherosclerotic progression, the significance of oxidized HDL remains to be clarified. The purpose of this study was to determine the relationships of oxidized HDL with blood coagulation and fibrinolysis in patients with diabetes. The subjects were outpatients with type 2 diabetes (n = 163; median hemoglobin A1c, 6.9%). Activities of blood coagulation and fibrinolysis were evaluated by levels of thrombin-anti-thrombin complex (TAT) and plasmin-α2 plasmin inhibitor complex (PIC), respectively. Relationships of oxidized HDL with TAT and PIC were investigated by using linear regression analysis and logistic regression analysis. Oxidized HDL showed a significant inverse correlation with TAT and a marginally significant correlation with PIC (Spearman's rank correlation coefficient: TAT, - 0.205 [p < 0.01]; PIC, - 0.135 [p = 0.087]). Prevalence of high TAT was significantly lower in the 3rd tertile group for oxidized HDL than in its 1st tertile (20.4 vs. 5.6%, p < 0.05), and prevalence of high PIC was marginally significantly lower in the 3rd tertile group for oxidized HDL than in its 1st tertile (40.7 vs. 24.1%, p = 0.099). In multivariate logistic regression analysis using age, gender, smoking, alcohol drinking, BMI, hemoglobin A1c, therapy for dyslipidemia, therapy for diabetes and anti-coagulation therapy as explanatory variables, odds ratios for high TAT and high PIC in the 3rd tertile group for oxidized HDL versus its 1st tertile group were significantly lower than the reference level of 1.00 (high TAT: 0.19 [0.04-0.99], p < 0.05; high PIC: 0.33 [0.12-0.95], p < 0.05). The frequency of high TAT or high PIC was lower in the higher tertile group for oxidized HDL than in its lower tertile group. Thus, oxidized HDL is thought to be inversely associated with both blood coagulation and fibrinolysis in patients with type 2 diabetes.

Entities:  

Keywords:  Coagulation; Diabetes mellitus; Fibrinolysis; HDL cholesterol; Oxidized HDL

Mesh:

Substances:

Year:  2018        PMID: 29247447     DOI: 10.1007/s11239-017-1594-x

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  25 in total

Review 1.  Coagulation and fibrinolysis in diabetes.

Authors:  S H Alzahrani; R A Ajjan
Journal:  Diab Vasc Dis Res       Date:  2010-09-16       Impact factor: 3.291

2.  Inverse associations of HDL cholesterol and oxidized HDL with d-dimer in patients with type 2 diabetes mellitus.

Authors:  Shigeyuki Ebara; Mikio Marumo; Chika Yamabata; Ikumi Nishibe; Jun-Ichi Soneda; Jun Mukai; Makoto Ohki; Kagehiro Uchida; Ichiro Wakabayashi
Journal:  Thromb Res       Date:  2017-04-20       Impact factor: 3.944

3.  Oxidative susceptibility of apolipoprotein AI in serum.

Authors:  Takanari Nakano; Atsuo Nagata
Journal:  Clin Chim Acta       Date:  2005-07-07       Impact factor: 3.786

Review 4.  Diabetes mellitus: The linkage between oxidative stress, inflammation, hypercoagulability and vascular complications.

Authors:  Caroline Pereira Domingueti; Luci Maria Sant'Ana Dusse; Maria das Graças Carvalho; Lirlândia Pires de Sousa; Karina Braga Gomes; Ana Paula Fernandes
Journal:  J Diabetes Complications       Date:  2015-12-18       Impact factor: 2.852

Review 5.  HDL and atherothrombotic vascular disease.

Authors:  Wijtske Annema; Arnold von Eckardstein; Petri T Kovanen
Journal:  Handb Exp Pharmacol       Date:  2015

Review 6.  Therapy to reduce risk of coronary heart disease.

Authors:  Daniel J Rader
Journal:  Clin Cardiol       Date:  2003-01       Impact factor: 2.882

7.  Determination of LOX-1-ligand activity in mouse plasma with a chicken monoclonal antibody for ApoB.

Authors:  Yuko Sato; Norihisa Nishimichi; Atsushi Nakano; Kenji Takikawa; Nobutaka Inoue; Haruo Matsuda; Tatsuya Sawamura
Journal:  Atherosclerosis       Date:  2008-02-12       Impact factor: 5.162

8.  LOX index, a novel predictive biochemical marker for coronary heart disease and stroke.

Authors:  Nobutaka Inoue; Tomonori Okamura; Yoshihiro Kokubo; Yoshiko Fujita; Yuko Sato; Mamoru Nakanishi; Kazuki Yanagida; Akemi Kakino; Shin Iwamoto; Makoto Watanabe; Sayoko Ogura; Kazunori Otsui; Haruo Matsuda; Kagehiro Uchida; Ryo Yoshimoto; Tatsuya Sawamura
Journal:  Clin Chem       Date:  2010-01-21       Impact factor: 8.327

Review 9.  The discovery of LOX-1, its ligands and clinical significance.

Authors:  Ryo Yoshimoto; Yoshiko Fujita; Akemi Kakino; Shin Iwamoto; Tomohide Takaya; Tatsuya Sawamura
Journal:  Cardiovasc Drugs Ther       Date:  2011-10       Impact factor: 3.727

10.  Associations among apolipoproteins, oxidized high-density lipoprotein and cardiovascular events in patients on hemodialysis.

Authors:  Hirokazu Honda; Tsutomu Hirano; Masashi Ueda; Shiho Kojima; Shinichi Mashiba; Yasuyuki Hayase; Tetsuo Michihata; Kanji Shishido; Keiko Takahashi; Nozomu Hosaka; Misa Ikeda; Daisuke Sanada; Takanori Shibata
Journal:  PLoS One       Date:  2017-05-18       Impact factor: 3.240

View more
  3 in total

1.  The significance of coagulation and fibrinolysis-related parameters in predicting postoperative venous thrombosis in patients with breast cancer.

Authors:  Mengyu Pang; Fenglian Zhao; Pengyue Yu; Xiaohua Zhang; Hexin Xiao; Wang Qiang; Hongquan Zhu; Liyan Zhao
Journal:  Gland Surg       Date:  2021-04

2.  Effects of Exenatide on Coagulation and Platelet Aggregation in Patients with Type 2 Diabetes.

Authors:  Yaqin Zhang; Ruofei Chen; Yangyang Jia; Mingwei Chen; Zongwen Shuai
Journal:  Drug Des Devel Ther       Date:  2021-07-12       Impact factor: 4.162

3.  The relationship between insulin sensitivity and serum antithrombin 3 activity in patients with type 2 diabetes.

Authors:  Hong Wang; Jie Cao; Jian-Bin Su; Xue-Qin Wang; Dong-Mei Zhang; Xiao-Hua Wang
Journal:  Endocr Connect       Date:  2021-06-23       Impact factor: 3.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.